Loading...
Loading...
Deutsche Bank increases its price target $6 to $85 on Buy-rated Mead Johnson Nutrition
MJN on emerging market opportunities and US market share gains.
Deutsche Bank says, "Although Mead's stock has performed well with valuation reaching new heights, we nevertheless retain our BUY opinion. Particularly when focused LT, we see opportunity as emerging markets across Asia and Latin America grow rapidly, Mead continues to gain share and the U.S. market eventually rebounds."
MJN closed at $79.76 a share yesterday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in